Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2021)
13 slides from Biotron's shareholder meeting presentation, Nov 23, 2021
Slide 1: Biotron Limited AGM 23 November 2021
BIOTRON LIMITED (ASX:BIT) AGM 23 November 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Key Achievements 2020/2021 FY
Key Achievements 2020/2021 FY • Key milestone for HIV-1 program: • Commenced two clinical trials of BIT225 • Trials designed in consultation with international experts with key links to pharma • Designed specifically to solidify understanding of what BIT225 is doing and how it is doing it with focus
Slide 4: Key Achievements 2020/2021 FY (cont)
Key Achievements 2020/2021 FY (cont) • Expanded the SARS-CoV-2 program • Testing in relevant, robust animal model of COVID in USA laboratory • Results are imminent • Hepatitis B Virus (HBV) program • Progressed identification of potential lead to move into animal model(s) • Unique approach to tackli
Slide 5: HIV-1 Unmet Need
HIV-1 Unmet Need • Safe, effective antiretroviral drugs (ART) have been central to successfully keeping virus levels down in HIV+ people; Profound reductions in mortality, morbidly and transmission BUT • ART is not curative, latent viral reservoirs remain and reactivate • Immune reconstitution is on
Slide 6: BIT225 – A new class of anti-HIV drug
BIT225 – A new class of anti-HIV drug • There is no roadmap for HIV-1 cure/eradication • The BIT225-009 trial showed that there is a pathway to show clinical benefit for treating with BIT225 • BIT225 a first-in-class drug that uniquely combines direct acting antiviral with immunomodulatory activitie
Slide 7: BIT225-010 and 011 HIV-1 Trials
BIT225-010 and 011 HIV-1 Trials • Two trials were designed to generate specific data to show a clinical benefit with BIT225, and further explore key observations related to inflammation and immune activation in both treatment naïve and experienced populations • Assessing key biomarkers (immunologica
Slide 8: BIT225 and HIV-1 – Positioning
BIT225 and HIV-1 – Positioning • A safe and effective agent that in conjunction with ART reduces inflammation and leads to fewer HIV comorbidities, improved health and lessened healthcare costs • A safe and effective agent that in conjunction with ART leads to increased immune system recognition and
Slide 9: SARS-CoV-2
SARS-CoV-2 • Biotron’s approach has been to design new small molecule drugs that target the SARS-CoV-2 viroporin(s) • E protein is a viroporin • Multiple roles in the virus lifecycle • Entry into cells and exit of new virus particles from infected cells • Pathogenesis of disease resulting from the i
Slide 10: SARS-CoV-2 Program
SARS-CoV-2 Program Vaccines remain central to control of the pandemic but there is an urgent need for effective drugs to treat COVID in at-risk populations • Designed and synthesised >100 new compounds to target the SARS-CoV-2 E protein (oral drugs) • Screened for ability to inhibit replication of S
Slide 11: Hepatitis B Virus
Hepatitis B Virus • ~300 million worldwide chronically infected with HBV • Increased risk of significant liver disease, including liver failure and cancer • HBV causes up to 80% of liver cancers • 5 year survival of 15% • >780,000 die every year • as a consequence of HBV infection • Current treatmen
Slide 12: Biotron HBV Program
Biotron HBV Program • Over last 12 months Biotron has designed and tested a suite of new compounds to expand its portfolio of novel small molecule compounds with good activity against HBV • Extensive package of preclinical in vitro data includes evidence of reduction in cccDNA, HBsAg, and other rele
Slide 13: Summary
Summary • HIV-1 program is the prime focus • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to improve health outcomes in combination with ART • SARS-CoV-2 program is developing drugs with potential to reduce virus levels and immune dysfu